Get Dis.

We’re gonna be honest and say that we’re pretty rusty on systemic therapy for soft tissue sarcoma (STS). So when we saw the GeDDIS trial published last week in Lancet Oncology, we quickly brushed up on the fact that doxorubicin has been a mainstay treatment for decades in patients with advanced STS...and then quickly learned that the combination of gemcitabine and docetaxel didn’t do any better. But delving more into the study and the accompanying editorial, it becomes apparent there are still a lot of holes in the systemic therapy regimens for STS. For one, GeDDIS is criticized (by itself and others) for the choice of gemcitabine and docetaxel dosing. And on a broader scale, STS data in general continues to hobble from one disjointed effort to another in attempts to test a wide variety of chemo regimens on a very heterogeneous group of tumors. So what we really want you to get is that we still have a long way to go in finding the optimal systemic therapy(s) for STS(s).